John Bernard Buse - the UNC Department of Medicine

Buse, Curriculum Vitae p. 4 of 29 Updated: August 2008
18. Doerr ME and Buse JB. Management of Complications of Diabetes. In: Manual of Clinical
Problems in Adult Ambulatory Care, 3rd ed (L Dornbrand, AJ Hoole, RH Fletcher, eds).
Lippincott-Raven Publishers, Philadelphia. pp. 371-5, 1997.
19. Doerr ME and Buse JB. Management of Type II Diabetes. In: Manual of Clinical Problems
in Adult Ambulatory Care, 3rd ed (L Dornbrand, AJ Hoole, RH Fletcher, eds). Lippincott-
Raven Publishers, Philadelphia. pp. 364-71, 1997.
20. Buse JB and Doerr ME. Diabetic Ketoacidosis. In: Conn's Current Therapy 1997 (RE
Rakel, ed). W.B. Saunders Co., Philadelphia, PA. pp. 553-7, 1997.
21. Buse J and Doerr ME. The Pancreas. In: Handbook of Endocrinology, 3nd ed (GH Gass
and HM Kaplan, eds). CRC Press, Boca Raton. pp 297-314, 1996.
22. Buse JB and Polonsky KS. Ketoacidosis, HONKC and hypoglycemia. In: Principles of
Critical Care Medicine (JB Hall, GA Schmidt, LDH Woods, eds). McGraw Hill, New York,
NY. pp 1966-76, 1992.
23. Bell GI, Buse JB, Fukumoto H, Kayano T, Seino S. Glucose transporters - molecular
structure and function In: Genes and Gene Products in the Development of Diabetes
Mellitus - Basic and Clinical Aspects (J Nerup T Mandrup-Poulsen & B Hokfelt eds).
Excerpta Medica, Amsterdam. pp. 287-97, 1990.
24. Eisenbarth GS, Jackson R, Srikanta S, Powers A, Buse J, Mori H. Utilization of monoclonal
antibody techniques to study Type 1 (insulin dependent) diabetes mellitus. In: Immunology
in Diabetes (D Andreani U DiMario KG Federlin LG Heding eds). Kimpton Medical
Publications, London. pp 143-57, 1984.
25. Margolius HS and Buse JB. The renal kallikrein-kinin system. In: Hormonal Function and
the Kidney (BM Brenner and JH Stein eds). Churchill Livingstone, New York. pp 115-45,
1979.
Refereed Original Research:
1. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips
GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure of
diabetes? Diabetes Care. 2009; 32:2133-5.
2. Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth
S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA; Look AHEAD and
ACCORD Research Groups. Constructing common cohorts from trials with overlapping
eligibility criteria: implications for comparing effect sizes between trials. Clin Trials 6:416-
29, 2009.
3. Ambrosius WT, Danis RP, Goff Jr. DC, Greven CM, Gerstein HC, Cohen RM, Riddle MC,
Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA,
Seaquist LA, Felicetta JV, Chew EY for the ACCORD Study Investigators. Lack of
association between thiazolidinediones and macular edema in type 2 diabetes: The ACCORD
Eye Study. Archives of Ophthalmology, in press, expected publication January 2010.
4. Dungan K, Buse JB, Ratner RE. Effects of therapy in type 1 and type 2 diabetes mellitus
with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab
Res Rev. 2009; 25:558-65.
5. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC,Evans
GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK,
Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2
diabetes. Diabetologia. 2009 Aug 5. Epub.